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Effects of the long acting b agonist formoterol
on asthma control in asthmatic patients using
inhaled corticosteroids
T van der Molen, D S Postma, M O Turner, B Meyboom-de Jong, J L Malo,
K Chapman, R Grossman, C S de Graaff, R A Riemersma, M R Sears, on behalf of
The Netherlands and Canadian formoterol study investigators
Abstract formoterol group. PEF returned to base-
line following discontinuation of for-Background – The long acting b2 agonist
moterol, as did asthma symptom scores.formoterol has proved to be an effective
Thirty three patients treated with for-bronchodilator with a prolonged action of
moterol and 32 treated with placebo re-12–14 hours. However, the precise role of
quired treatment with prednisolone duringformoterol in the maintenance treatment
the study (58 and 55 courses, respectively).of asthma is still under debate. A study
Conclusions – Adding formoterol 24 lgwas performed to investigate the efficacy
twice daily by Turbohaler to inhaledand safety of treatment with formoterol
corticosteroids was effective in improvingfor six months in subjects with asthma.
symptom scores and morning PEF, andMethods – In a multicentre double blind,
decreasing the use of rescue b2 agonists.placebo controlled, parallel group study
There was no apparent loss of asthma con-239 subjects with mild to moderate asthma
trol during 24 weeks of treatment withwere randomly assigned to treatment with
formoterol.either inhaled formoterol 24 lg twice daily
(Thorax 1997;52:535–539)(n=125) or placebo (n=114) during eight
months. The study consisted of a four week
Keywords: formoterol, long acting b agonists, asthma,run in period, a 24 week treatment period,
inhaled corticosteroids.and a four week washout period. All sub-
jects were using regular inhaled cortico-
steroids (100–3200 lg daily) but were still Inhaled b2 adrenoceptor agonists are the most
needing at least five inhalations of short frequently used treatment in mild asthma and
acting b2 agonist per week for symptom are of crucial importance in the treatment of
relief. The study was performed in 10 out- acute bronchoconstriction.1 However, their
patient clinics in Canada, and five out- role in chronic maintenance treatment is con-
patient clinics and one coordinating centre troversial due to limited efficacy and has even
for 44 Dutch general practitioners in The caused some concern. Several studies have
Netherlands. Twice daily self-reported shown a decrease in control of symptoms or
peak expiratory flow (PEF) measure- a more rapid deterioration of lung function
ments, symptom scores, and rescue b2 associated with regular use of b2 agonists as
agonist use during the last 28 treatment opposed to “if needed” treatment.2–4 Other
days compared with baseline values were studies have also reported mild tachyphylaxis
used as main outcome measures. Spiro- to continuous b2 agonist therapy but the
metric values were measured at entry, at changes were small and of doubtful clinical
the start of treatment, after four, 12 and significance.5 6 The poor efficacy of main-
24 weeks of treatment, and after four weeks tenance treatment with short acting b2 agonists
washout. compared with “if needed” treatment does not
Results – One hundred and twenty five seem to be influenced by anti-inflammatory
subjects received formoterol 24 lg twice treatment with inhaled corticosteroids.7 There
daily via Turbohaler and 114 received is no evidence that these concerns and the
placebo. Baseline FEV1 was 67.1% pre- limited efficacy of maintenance treatment with
dicted and mean bronchodilator re- short acting b2 agonists apply also to long acting
versibility was 26%. The mean total b2 agonists. Since the use of a long acting
asthma symptom score was 3.6 (maximum bronchodilator provides “regular” treatment,
possible 21). A significant decrease inCorrespondence to: it is important to investigate the efficacy and
Professor Dr D S Postma, symptoms in favour of formoterol (differ- safety of maintenance treatment with long act-Department of Pulmonology,
ence from placebo−0.64, 95% CI−0.04 toUniversity Hospital, ing b2 agonists in a sufficient number of subjects
Hanzeplein 1, PB 30.001, −1.23, p=0.04) was observed. Compared over a prolonged period.9700 RB Groningen,
The Netherlands. with placebo, morning PEF increased We have undertaken a multicentre, long
(difference from placebo 28 l/min, 95% CIReceived 5 September 1996 term, placebo controlled study on the effects
Returned to authors 18.3 to 37.7, p=0.0001) and the use of short of the long acting b2 agonist formoterol in6 November 1996
acting b2 agonists decreased (daytimeRevised version received asthmatic subjects already using inhaled
5 February 1997 difference from placebo −1.1 inhalation, corticosteroids. The aim of the study was toAccepted for publication
10 February 1997 95% CI −1.4 to −0.7, p=0.0001) in the assess the effect of regular formoterol on asthma
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taken on entry was kept constant throughoutTable 1 Mean (SD) characteristics of the patients in the formoterol and placebo groups
at the beginning of the run-in period the study. Terbutaline (250 lg inhalations via
Turbohaler) was allowed as needed for reliefFormoterol Placebo
(n=125) (n=114) of symptoms. No long acting b2 agonists were
allowed with the exception of the study med-Age (years) 40.5 (13.7) 45.4 (14.0)
Male (%) 48.8 49.2 ication. Theophyllines were stopped at least
Atopy (%) 68.8 66.6 four days before the first visit.Current smoking (n) 18 12
Smoking (pack years) 10.1 (7.1) 8.1 (4.1) At the end of the run-in period at the second
FEV1 (l) 2.29 (0.7) 2.16 (0.8) visit subjects were randomly assigned to receive(% predicted) 68 (15) 66 (16)
Post bronchodilator FEV1 (l) 2.85 (0.8) 2.69 (0.9) either formoterol (two inhalations of 12 lg
Reversibility (% baseline) 25.2 (11.8) 26.3 (13.1) twice daily) or placebo via a dry powder inhaler
Run-in values
(Turbohaler). Randomisation was performedPEF morning (l/min) 392 (99.3) 382 (101.4)
PEF evening (l/min) 412 (97.7) 406 (97.5) in blocks of four to one of the two treatment
Symptom score total (max 21) 3.7 (2.8) 3.6 (3.0) groups of equal size. Subjects came to the clinicRescue inhalations during day 2.4 (1.9) 2.0 (1.4)
Rescue inhalations during night 1.4 (1.2) 1.4 (0.9) on six occasions: on entry, after the four week
Dose of inhaled steroid (n)∗ run-in period, at weeks four, 12 and 24 of
Ζ400 lg 23 22
the treatment period, and after the four week401–800 lg 28 19
801–1600 lg 51 48 washout period. Subjects were instructed not
[1600 lg 20 24 to take their morning dose of formoterol or
FEV1=forced expiratory volume in one second; PEF=peak expiratory flow. placebo, and not to use supplemental ter-
∗Doses are expressed as equipotent doses. Four patients were not classified because they were butaline for six hours before clinic visits.using irregular doses.
At each visit (and at the same time for each
subject), FEV1, blood pressure, and pulse rate
were measured, and questions about adversecontrol as judged by daily peak flow meas-
urements, symptom scores, and frequency of events were asked. The primary variable in
the study was the total daily score of asthmaexacerbations.
symptoms. Subjects therefore filled in daily
diary cards to record daytime symptoms of
chest discomfort, sputum production, cough,Methods
 activity, and wheezing on a scale ranging from
0=none to 3=very severe. Night time symp-Two hundred and thirty nine adult asthmatic
subjects (table 1) were studied for eight months toms of wheeze and cough were recorded on
the same scale adding up to a total asthma(six months of treatment). The study was per-
formed from June 1992 until October 1994 at symptom score of 21. From previous studies
of similar design it was estimated that, with16 centres, six in The Netherlands and 10 in
Canada. Sixty five subjects in The Netherlands 100 patients in each treatment group, there
was an 80% chance of detecting a true meanwere recruited from 44 general practitioners to
a coordinating centre and 45 from five out- difference of about 1.6 units in the change in
score between the two treatment groups whenpatient hospital clinics. All 129 subjects in
Canada were recruited from 10 outpatient hos- using a test at the 5% significance level. This
was based on the assumption that the standardpital clinics.
Inclusion criteria were asthma according to deviation of the change for the total score was
about 4 units. The highest of three meas-the definition of the American Thoracic So-
ciety,8 regular use of any dose of inhaled cortico- urements of peak expiratory flow (PEF) by
mini-Wright peak flow meter was recorded eachsteroids, the use of at least five inhalations of
a short acting b2 agonist per week before the morning and evening, together with use of
day and night time bronchodilators and otherentry visit, and >15% reversibility in baseline
forced expiratory volume in one second (FEV1) medication. PEF was measured before inhala-
tion of the study drug, and the subjects wereafter two inhalations of 250 lg terbutaline (Bri-
canyl Turbohaler, Astra Draco, Sweden) or asked to refrain from the use of terbutaline at
least six hours before a measurement. If therethe equivalent dose of salbutamol. Exclusion
criteria were the use of oral corticosteroids at was a 20% drop from run-in values in morning
PEF during two consecutive days, the subjectany time in the last month, smoking history of
>20 pack years, FEV1 of <40% predicted, or telephoned the investigator who then initiated
an oral prednisolone course for treatment of thean exacerbation of asthma symptoms during
the previous month. The use of cromoglycate, exacerbation. All lung function measurements
were made between 08.00 and 12.00 hours. b2theophylline, and anticholinergic drugs was not
allowed during the study. agonists were stopped at least six hours before
each test. FEV1 was measured with a calibratedThe study protocol was approved by the
medical ethics committees of all participating spirometer according to standardised guide-
lines.9 At least three reproducible values (<5%centres. All subjects gave written informed con-
sent. difference) were obtained and the highest value
was used in the analyses.
 
A double blind, placebo controlled, parallel   
The primary variables of investigation weredesign was used with a run-in period of four
weeks to obtain baseline values, a treatment total asthma symptom score (sum of seven
items; minimum score 0, maximum score 21)period of 24 weeks, and a washout period of
four weeks. The dose of inhaled corticosteroids and morning PEF recorded in diaries. PEF was
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steroids were used and the doses are expressedTable 2 Reasons for discontinuation during treatment
period in equipotent doses. Ninety two (38.5%) sub-
jects used less than 800 lg, 99 (41.4%) usedPlacebo Formoterol
800–1600 lg, and 44 (18.4%) used more than
Asthma deterioration 6 1 1600 lg of any kind of inhaled corticosteroidAdverse event 1 5
Non-compliance 2 4 daily. Despite instructions to the contrary, four
Unspecified reasons 4 8 subjects varied their dosage of inhaled cortico-
Total 13 18 steroid.
Two hundred and eight subjects completed
the study. Thirteen subjects using placebo and 18
subjects using formoterol discontinued treatmentmeasured 12 hours after the last intake of study
(table 2). Discontinuation due to deteriorationdrug, thus reflecting the remaining effect of
of asthma was higher in the placebo group (n=formoterol. Daily means, where missing data
6) than in the formoterol group (n=1). Dis-were substituted according to the last value
continuation due to adverse events in the for-extended principle, were used to illustrate the
moterol group (n=5) was caused by tremor (3),lung function and asthma symptoms during
bronchospasm (1), and rash (1).the entire study. The primary end point was
the change from the run-in period (mean value
over the last 14 days) to the end of the treatment
 period (mean value over the last 28 days).
Results of the total symptom scores are pre-Comparisons of the treatments were performed
sented in fig 1. In the formoterol group a smallusing an analysis of variance model with the
but statistically significant reduction in totalfactors treatment and centre. Run-in values
symptom score occurred (difference betweenwere used as covariates. The “all patients
end of run-in period and end of treatment=treated” approach was applied. A significance
1.28) which lasted the whole treatment periodlevel of 5% was used.
and returned to baseline values immediately
after the start of the washout period (difference
between run-in and washout periods=0.2).Results
The placebo group reported a smaller changeTwo hundred and eighty subjects entered the
in symptom scores (0.64). The difference inrun-in period of the study, and 239 subjects
the change in symptom scores between the twowere randomised to two parallel treatment
groups (0.64) was significant (p=0.039; 95%groups. Those receiving formoterol 24 lg twice
CI 1.23 to 0.04) and largely reflected changesdaily (n=125) and placebo (n=114) had sim-
in wheeze at night and chest discomfort. Bothilar characteristics (table 1). The mean age of
of these scores changed from 0.6 (last 14 days inthe subjects was 42.8 years and the duration
run-in period) to 0.3 (last 28 days of treatmentof asthma was 20.6 years. Mean pre-broncho-
period) in the formoterol group, whereas thedilator FEV1 was 67.1% of predicted normal,
placebo group showed no difference. The meanand mean reversibility was 25.7% at baseline.
(SD) change in the total symptom score duringThe dose of inhaled corticosteroids ranged
treatment with formoterol was −1.6 (2.6) infrom 100 lg to 3200 lg daily. Many kinds of
the low dose steroid group (Ζ400 lg) and
−1.1 (2.9) in the high dose steroid group
([1600 lg).
  ()
Mean morning and evening PEF during the
study are shown in fig 2. The mean changes
in morning and evening PEF values from the
last two weeks of the run-in period to the last
four weeks of the treatment period were 25.9 l/
min (morning) and 21.2 l/min (evening) in the
formoterol group and −2.1 l/min (morning)
and−5.9 l/min (evening) in the placebo group.
The mean difference between the two groups
was highly significant (morning PEF 28 l (95%
CI 18 to 38), p<0.001; evening PEF 27.1 (95%
CI 17 to 37), p<0.001) and remained stable
during the 24 weeks of treatment. Mean (SD)
morning peak flow in the formoterol group was
391.6 (99.3) l in the last 14 days of the run-
in period, and 393.4 (107.1) l in the washout
period. Placebo values were 382.0 (101.4) l and
383.9 (103.5) l, respectively. The mean im-
provement in morning peak flow in the for-
moterol group was independent of the dose of
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32.8 l), the difference being not statisticallyFigure 1 Daily mean total symptom scores before, during, and after treatment with
formoterol or placebo. significant (p=0.55).
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 
The number of courses of oral prednisolone
used during the treatment period provided an
indication of the total number of asthma ex-
acerbations. Thirty two (28.1%) of the 114
subjects in the placebo group had 55 pred-
nisolone courses and 33 (26.4%) of the 125
subjects in the formoterol group had 58
courses. The difference between the two groups
was not statistically significant.
Discussion
The effect of adding inhaled formoterol, 24 lg
twice daily, to inhaled corticosteroids in the
treatment of asthmatic subjects was superior
to placebo. Subjects treated with formoterol
improved according to every variable in the
study (daily symptom scores, PEF, requirement
of additional bronchodilator use for symptom
relief, and FEV1) independently of steroid dose.
The reported effects on PEF and FEV1 were
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350
moterol and are therefore minimum effects.
Figure 2 Daily mean morning peak flow values before, during, and after treatment with Although desensitisation of b2 receptors leading
formoterol or placebo. to a reduction in response would be noticed
first on these effects, we did not find a reduction
in response in any of the clinical variables
tested, nor a worsening of asthma during the
six months of treatment with formoterol. The
mean difference in symptom scores between1
Mean (SD) FEV1 at the start of the treatment formoterol and placebo remained small but
stable. Only six subjects discontinued the studyperiod was 2.38 (0.77) l in the formoterol group
and 2.21 (0.79) l in the placebo group. The because of asthma deterioration, five of them
in the placebo group.mean FEV1 in the formoterol group changed
from 2.38 l at baseline to 2.57 (0.85) l after These results are consistent with the benefits
seen in several other long term studies withfour weeks of treatment and to 2.51 (0.85) l
after 24 weeks of treatment. In the placebo long acting b2 agonists.10–13 None of the studies
has shown substantive evidence that treatmentgroup the mean FEV1 changed from
2.21 (0.79) l to 2.26 (0.82) l after four weeks with long acting b2 agonists has deleterious
effects on asthma control. The available longof treatment and to 2.25 (0.84) l at the end of
the treatment period. The change in FEV1 from term studies show maintenance of a constant
bronchodilating effect and symptom control.baseline was consistently larger with formoterol
than placebo, the difference in the change be- In a multicentre study with 301 subjects Hek-
king et al13 compared formoterol (12 lg inhala-tween the groups being 0.18 l (95% CI 0.08 to
0.28) at week 8, 0.11 l (95% CI 0.00 to 0.21) tion twice daily) with salbutamol (200 lg
inhalation four times daily) for 12 weeks. Theat week 16, and 0.12 l (95% CI 0.02 to 0.22)
at week 28. At the end of the washout period mean morning PEF in the formoterol group
was 37 l/min higher than in the salbutamol(week 32) there was no difference in the FEV1
between the two groups. There were no in- group, and the mean numbers of recorded
asthma attacks per week were 1.7 and 2.8,dications of a difference in FEV1 over time
between the two treatment groups (p=0.21). respectively, the difference being statistically
significant. In another study by Kesten and co-
workers14 inhaled formoterol in a dose of 12 lg
twice daily provided better symptomatic con- 
The mean daytime use of rescue medication trol of asthma accompanied by reduced diurnal
variation in PEF than inhaled salbutamol in a(terbutaline 250 lg) in the formoterol treat-
ment group decreased by 1.5 inhalations from dose of 200 lg four times daily in a three month
double blind study. In a 12 month follow uprun-in (mean 2.4) to treatment (mean 0.9) and
returned to baseline values after the beginning study the improvements in asthma control and
lung function were maintained at the levelsof the washout period (mean 2.2). Mean night
time rescue medication use decreased by 0.9 reached in the three month study.11 Studies
with another long acting b2 agonist, salmeterol,inhalations from 1.5 to 0.6 with a smaller
decrease in the placebo group (−0.4 and−0.2, reported similar findings.15 16 A recent report
on the effects of added salmeterol in subjectsrespectively). The difference between the two
groups was highly significant (daytime −1.1 already treated with inhaled corticosteroids10
showed better symptom control and higher(95% CI−1.4 to −0.7), p<0.001; night time
−0.8 (95% CI −1.0 to −0.5), p<0.001) and mean morning and evening PEF in the sal-
meterol treated group than in the group treatedremained stable throughout the treatment
period. with increased doses of corticosteroids. In a
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The authors would like to thank the Canadian formoterol12 month comparison between salmeterol and investigators, N Balter (Toronto), M Desmeules (Saint-Foy),
J Fleetham (Vancouver), R Hyland (Toronto), R Rivingtonsalbutamol Britton et al17 showed a clear im-
(Ottawa), M Y Rouleau (Quebec City), P Warren (Winnipeg)provement in PEF and symptom scores in and the Dutch formoterol investigators, A J M Schreurs (Am-
sterdam), H H Berendsen (Den Haag), J L M van Helmondthe salmeterol group. The mean difference in
(Roosendaal), and P M Hooghiemstra (Amsterdam). We alsoimprovement in morning PEF between the thank the Dutch general practitioners who cooperated in this
study. The study was supported by Astra Draco AB Sweden.groups in their study was 30 l/min, slightly
more than the 26 l/min reported here. However, 1 Barnes PJ. A new approach to the treatment of asthma. N
Engl J Med 1989;321:1517–27.formal comparisons of studies with salmeterol
2 van Schayck CP, Dompeling E, van Herwaarden CLA,
and formoterol to address the issue of whether Folgering H, Verbeek ALM, van der Hoogen HJM, et al.
Bronchodilator treatment in moderate asthma or chronicthe drugs have different efficacies is not pos-
bronchitis: continuous or on demand? A randomised con-
sible. The inclusion criteria in the two studies trolled study. BMJ 1991;303:1426–31.
3 Wahedna I, Wong CS, Wisniewski AFZ, Pavord ID, Tat-were different so the results were being assessed tersfield AE. Asthma control during and after cessation
in asthma of different severity. Further studies of regular beta2-agonist treatment. Am Rev Respir Dis
1993;148:707–12.are needed to establish whether these drugs 4 Sears MR, Taylor DR. The b2-agonist controversy. Ob-
servations, explanations,and relationship to asthma epi-have a similar effectiveness.
demiology. Drug Safety 1994;2:259–83.In contrast to the studies with long acting b 5 O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non-
bronchodilator effects of inhaled beta2-agonists in asthma.agonists, regular treatment with short acting b2
N Engl J Med 1992;327:1204–8.agonists has shown deleterious effects in some 6 Dompeling E, van Schayck CP, van Grunsven PM, van
Herwaarden CLA, Akkermans R, Molema J, et al. Slowingstudies. Kraan et al18 suggested that an increase
the deterioration of asthma and chronic obstructive pul-in airway hyperresponsiveness occurred with monary disease observed during bronchodilator therapy
by adding inhaled corticosteroids. A 4 year prospectiveregular use of inhaled short acting b2 agonists, study. Ann Intern Med 1993;118:770–8.
while the converse was true among subjects 7 Sears MR, Taylor DR, Print CG, Lake DC, Li Q, Flannery
EM, et al. Regular inhaled beta-agonist treatment in bron-taking inhaled corticosteroids. In other studies
chial asthma. Lancet 1990;336:1391–6.
reporting the negative effects of regular short 8 American Thoracic Society. Standards for the diagnosis and
care of patients with chronic obstructive pulmonary diseaseacting b2 agonist therapy the detrimental effect (COPD) and asthma. Am Rev Respir Dis 1987;136:225–44.
seems not to be affected by inhaled cortico- 9 Quanjer PH. Standardized lung function testing. Bull Eur
Physiopathol Respir 1983;19(Suppl 5):1–95.steroids.7 However, no deleterious effects were 10 Greening AP, Ind PW, Northfield M, Shaw G, Allen &
Hanburys Limited UK Study Group. Added salmeterolseen in our study when formoterol was added
versus higher-dose corticosteroid in asthma patients withto inhaled corticosteroids for a period of six symptoms on existing inhaled corticosteroid. Lancet 1994;
344:219–24.months. This was true for side effects, numbers
11 Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH,of exacerbations, additional use of broncho- Knight A, et al. Sustained improvement in asthma with
long term use of formoterol fumarate. Ann Allergy 1992;dilators, and lung function variables. The pres-
69:415–20.ent study, which is the first double blind study 12 Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide
surveillance study: comparison of salmeterol with sal-with a period of observation lasting six months,
butamol in asthmatic patients who require regular
therefore suggests that formoterol is a safe drug bronchodilator treatment. BMJ 1993;306:1034–7.
13 Hekking PR, Maesen F, Greefhorst A, Prins J, Tan I,when used with inhaled corticosteroids.
Zweers P. Long-term efficacy of formoterol compared to
In summary, inhaled formoterol fumarate in salbutamol. Lung 1990;Suppl:76–82.
14 Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH,a dose of 24 lg twice daily is an effective long Knight A, et al. A three-month comparison of twice daily
inhaled formoterol versus four times daily inhaled albuterolacting b2 agonist that provides sustained im-
in the management of stable asthma. Am Rev Respir Disprovement in asthma symptoms and objective 1991;144:622–5.
15 Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol andmeasures of lung function during prolonged
salbutamol in asthmatic patients. Am Rev Respir Dis 1990;maintenance treatment in subjects who were 142:571–5.
16 Lo¨tvall J, Lunde H, Ullman A, To¨rnqvist H, Svedmyralso using inhaled corticosteroids. The efficacy
N. Twelve months, treatment with inhaled salmeterol inwas maintained throughout the treatment asthmatic patients: effects on beta2-receptor in asthmatic
patients. Allergy 1992;47:477–83.period. Although the place of long acting b2 17 Britton MG, Earnshaw JS, Palmer JB. A twelve month
agonists in the management of asthma is still comparison of salmeterol with salbutamol in asthmatic
patients. Eur Respir J 1992;5:1062–7.under discussion, our results suggest that reg-
18 Kraan J, Koe¨ter GH, van der Mark ThW, Sluiter HJ, de
ular treatment with long acting b2 agonists in Vries K. Changes in bronchial hyperreactivity induced by
4 weeks of treatment with antiasthmatic drugs in patientsconjunction with inhaled corticosteroids is safe with allergic asthma: a comparison between budesonide
and terbutaline. J Allergy Clin Immunol 1985;76:628–36.and often helpful.
